Knight Therapeutics (TSE:GUD) Reaches New 1-Year High – Here’s What Happened

Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high on Thursday . The company traded as high as C$10.19 and last traded at C$10.16, with a volume of 7628 shares trading hands. The stock had previously closed at C$10.01.

Knight Therapeutics Stock Up 2.3%

The firm has a market cap of C$1.01 billion, a price-to-earnings ratio of 68.27, a P/E/G ratio of -1,013.50 and a beta of -0.29. The firm’s fifty day moving average is C$9.73 and its two-hundred day moving average is C$8.59. The company has a debt-to-equity ratio of 4.29, a current ratio of 2.28 and a quick ratio of 1.79.

Knight Therapeutics (TSE:GUD) last released its earnings results on Thursday, August 6th. The company reported C($0.03) EPS for the quarter. The company had revenue of C$143.97 million for the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. On average, sell-side analysts expect that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.